Saturday, May 04, 2024 11:19:00 AM
Had a great discussion with a few research scientist and business owner regarding the potential NVP for NWBO given approval for DCVax-L, IMPO.
Would cancer statistics
https://www.wcrf.org/cancer-trends/worldwide-cancer-data/#:~:text=Brain%2C%20central,nervous%20system%20308%2C102
https://www.bing.com/search?q=what+is+the+estimated+costs+factor+for+DCVax-L+if+approved&qs=n&form=QBRE&sp=-1&ghc=1&lq=0&pq=what+is+the+estimated+costs+factor+for+dcvax-l+if+approved&sc=10-58&sk=&cvid=C9ECAE761CB44E92BE35551BCFC4063B&ghsh=0&ghacc=0&ghpl=&showconv=1
My question,
What is the estimated costs factor for DCVax-l if approved
Copilot response,
The estimated cost factor for DCVax-L, if approved, is expected to be substantially below the price range of most antibody drugs and “targeted” cancer drugs. These types of drugs are typically priced at around $60,000 to $80,000 per year, and in some cases, they can even exceed $100,000 per year1. To put this into context, let’s compare it to another cancer treatment:
DCVax-L, Brain Cancer
World cancer data,
Rank Cancer New cases in 2020 % of all cancers
19 Brain, central nervous system 308,102 1.7
Per year S-Curve timeline analysis costs based on only 25% market
DCVax-L estimated costs $60,000.00 $80,000.00
S-Curve % (over two years)
Patient's Total sales at $60K Total sales at $80K
2 6000 $360,000,000.00 $480,000,000.00
10 30000 $1,800,000,000.00 $2,400,000,000.00
25 75000 $4,500,000,000.00 $6,000,000,000.00
45 135000 $8,100,000,000.00 $10,800,000,000.00
What if DCVax-D is approved in a few years and can help cure all solid tumors for the leading cancers throughout the world?
Now consider what for potential NVP for NWBO given approval for DCVax-D, IMPO.
World cancer data,
Rank Cancer New cases in 2020 % of all cancers
1 Breast 2261419 12.5
Per year S-Curve timeline analysis costs based on only 25% market
DCVax-D estimated costs $60,000.00 $80,000.00
S-Curve % (over two years)
Patient's Total sales at $60K Total sales at $80K
2 45228 $2,713,702,800.00 $3,618,270,400.00
10 226142 $13,568,514,000.00 $18,091,352,000.00
25 565355 $33,921,285,000.00 $45,228,380,000.00
45 1017639 $61,058,313,000.00 $81,411,084,000.00
Now consider the other top cancer rates based on solid tumors. You get the picture, IMPO.
The bottom line indicates the value of NWBO revenue (GBM) could value the stock price could be worth $16 to $25, DCVax-L, IMPO
The bottom line indicates the value of NWBO revenue (Breast) could value the stock price could be worth $120 to $160, DCVax-D, IMPO
Now add the other top 10 cancers based on solid tumor cancer could very well be worth 5X to 10X the value of DCVax-D alone, IMPO.
Keep in mind, the S-Curve analysis is based on only a 25% market share and over a two year period for DCVax-L, IMPO.
Keep in mind, the S-Curve analysis is based on only a 25% market share and over a two year period for DCVax-D, IMPO.
You do the math, and you can clearly see that the overall potential value for NWBO's revenue and stock price could be worth hundreds of $$$ billions, IMPO.
Praying for DCVax-L approval as soon as possible followed by DCVax-D approval as soon as possible.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM